Goldschmidt, H
Lokhorst, H M
Mai, E K
van der Holt, B
Blau, I W
Zweegman, S
Weisel, K C
Vellenga, E
Pfreundschuh, M
Kersten, M J
Scheid, C
Croockewit, S
Raymakers, R
Hose, D
Potamianou, A
Jauch, A
Hillengass, J
Stevens-Kroef, M
Raab, M S
Broijl, A
Lindemann, H W
Bos, G M J
Brossart, P
van Marwijk Kooy, M
Ypma, P
Duehrsen, U
Schaafsma, R M
Bertsch, U
Hielscher, T http://orcid.org/0000-0003-1277-310X
Jarari, Le
Salwender, H J
Sonneveld, P
Article History
Received: 18 April 2017
Revised: 10 June 2017
Accepted: 20 June 2017
First Online: 4 July 2017
Competing interests
: EKM: Honoraria: Janssen-Cilag, Takeda; Advisory boards: Takeda; Other support (travel grants): Janssen-Cilag, Takeda, Celgene, Onyx and Mundipharma; PS: Research support from Janssen, Celgene, Amgen, Takeda, Karyopharm Honoraria and advisory boards: Janssen, Celgene, Amgen, Takeda, Karyopharm; MSR: Research Support from Novartis, Amgen, Morphosys; Consulting for Novartis, Amgen, Celgene, Janssen; JH: Advisory boards: Celgene, Janssen, Novartis; Speakers honoraria: Celgene, Janssen, BMS, Amgen; Consultancy: Amgen; Travel support: Amgen, BMS, Takeda; Research Support: Novartis, Sanofi; HJS: Honoraria: Janssen, Celgene; Travel support: Janssen, Celgene; KCW: Consultancy: Amgen, Bristol Myers Squibb, Celgene, Novartis, Janssen, Takeda; Honoraria: Amgen, Bristol Myers Squibb, Celgene, Novartis, Janssen, Takeda; Research funding: Celgene, Janssen; IWB: Research grant: Celgene and Janssen; Advisory boards: Janssen, Celgene, Amgen, Takeda, Novartis, BMS; PS: SkylineDx: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Research Funding; Amgen: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; SZ: Celgene: Honoraria, Research Funding; Takeda Millennium: Honoraria, Research Funding; Onyx: Honoraria; Annemiek Broijl: Amgen: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Christ of Scheid: Janssen: Honoraria; Celgene: Honoraria; AP: Janssen: Employment; Dirk Hose: Takeda: Other: Travel grant; EngMab AG: Research Funding; M-JK: Takeda Millennium: Research Funding; Janssen: Honoraria, Research Funding; Roche: Honoraria, Research Funding; UD: Alexion: Honoraria; Janssen: Honoraria; HML: Janssen: Honoraria, Research Funding; Genmab: Honoraria, Research Funding; Amgen: Honoraria; Goldschmidt: Celgene: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Chugai: Honoraria, Research Funding; Onyx: Honoraria, Research Funding; Millennium: Honoraria, Research Funding; BMS: Honoraria, Research Funding. The remaining authors declare no conflict of interest.